Drug Database · Food supplement

RENADYL

Bifidobacterium longum, Streptococcus thermophilus, Lactobacillus acidophilus

Food supplementKidney-marketedProbiotic1 registration Kidney notes reviewed
Company: GOODFELLOW PHARMA CORPORATION Last updated: Audience: Licensed health professionals
Registered with the Philippine FDA as a FOOD SUPPLEMENT — no approved therapeutic claims. Not a substitute for prescribed treatment.

Kidney notes

Renadyl is a three-strain probiotic (Streptococcus thermophilus, Lactobacillus acidophilus, Bifidobacterium longum) marketed for 'enteric dialysis', the idea that gut bacteria can metabolize urea and other nitrogenous waste. It is the only kidney-marketed supplement in this list with published trials of the product itself, all small and most sponsored or co-authored by its maker, Kibow Biotech.

Evidence

  • Ranganathan 2009 (Canada): 6-month double-blind, placebo-controlled crossover pilot in 16 patients with CKD stages 3 to 4 (13 completed). BUN fell during probiotic periods versus placebo (mean change -2.93 vs +4.52 mmol/L, p = 0.002); creatinine did not change significantly. Sponsor-authored.
  • Ranganathan 2010 (four countries): 6-month crossover pilot in 46 patients with CKD stages 3 to 4 at 90 billion CFU/day. BUN fell in 63% of patients; creatinine and uric acid changes were not significant. Authors note small size and inconsistencies. Sponsor-authored.
  • Natarajan 2014 (hemodialysis): double-blind crossover RCT, 22 of 28 completed. No statistically significant change in uremic toxins or quality of life; trends only for white cell count, CRP and indoxyl glucuronide. Safe over 2-month periods.
  • Kalidindi 2024 (India): open-label RCT, 60 patients with CKD stages 3 to 4, Renadyl versus another probiotic (Lobun Forte) for 6 months, no placebo arm. Both arms reported lower indoxyl sulfate, BUN and creatinine. Co-authored by the comparator's manufacturer.
  • Class evidence: a meta-analysis of 14 RCTs found microbiota-directed therapy lowered p-cresyl sulfate but not indoxyl sulfate, and probiotics alone did not lower either (Chen 2022); a meta-analysis of 12 RCTs in non-dialysis patients found no effect of prebiotics, probiotics or synbiotics on serum creatinine (Liu 2023).

Cautions in kidney disease

  • Probiotic organisms can enter the bloodstream: whole-genome sequencing has linked Lactobacillus bacteremia in ICU patients to the probiotic capsule they were given. Avoid in critically ill patients, those with a central venous catheter (including a tunneled hemodialysis catheter), recent bowel surgery or gut barrier injury, and in kidney transplant recipients or others on immunosuppression unless the treating team agrees. [Yelin 2019]
  • Trial outcomes were blood urea nitrogen (BUN), creatinine, uremic-toxin levels and quality-of-life scores; no trial reports kidney failure, dialysis start, cardiovascular events or death.
  • Registered as a food supplement with no approved therapeutic claims: viable count, strain identity and storage stability are not verified by the FDA the way drug content is.
  • It does not replace evidence-based CKD care (blood pressure and glucose control, RAAS blockade, SGLT2 inhibitors where indicated, diet).

Bottom line

Small, mostly sponsor-linked trials show changes in BUN or uremic toxins at best, with no evidence on kidney or patient outcomes. Reasonable to tolerate in a stable outpatient who wants it; avoid in transplant recipients, the immunosuppressed, the critically ill and patients with a dialysis catheter; never a substitute for proven CKD therapy.

Sources

  1. Ranganathan, N., Friedman, E. A., Tam, P., Rao, V., Ranganathan, P., & Dheer, R. (2009). Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: A 6-month pilot scale trial in Canada. Current Medical Research and Opinion, 25(8), 1919–1930. https://doi.org/10.1185/03007990903069249
  2. Ranganathan, N., Ranganathan, P., Friedman, E. A., Joseph, A., Delano, B., Goldfarb, D. S., Tam, P., Rao, A. V., Anteyi, E., & Musso, C. G. (2010). Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Advances in Therapy, 27(9), 634–647. https://doi.org/10.1007/s12325-010-0059-9
  3. Natarajan, R., Pechenyak, B., Vyas, U., Ranganathan, P., Weinberg, A., Liang, P., Mallappallil, M. C., Norin, A. J., Friedman, E. A., & Saggi, S. J. (2014). Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. BioMed Research International, 2014, 568571. https://doi.org/10.1155/2014/568571
  4. Kalidindi, R. K., Reddy, C. P., Pv, K., & Kompella, P. (2024). The efficacy and safety of probiotic combinations Lobun Forte® versus Renadyl® in patients with chronic kidney disease: A comparative, phase IV, randomized, open-label, active-controlled, parallel study. Cureus, 16(8), e67987. https://doi.org/10.7759/cureus.67987
  5. Chen, L., Shi, J., Ma, X., Shi, D., & Qu, H. (2022). Effects of microbiota-driven therapy on circulating indoxyl sulfate and p-cresyl sulfate in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. Advances in Nutrition, 13(4), 1267–1278. https://doi.org/10.1093/advances/nmab149
  6. Liu, F., Liu, Y., Lv, X., & Lun, H. (2023). Effects of prebiotics, probiotics and synbiotics on serum creatinine in non-dialysis patients: A meta-analysis of randomized controlled trials. Renal Failure, 45(1), 2152693. https://doi.org/10.1080/0886022X.2022.2152693
  7. Yelin, I., Flett, K. B., Merakou, C., Mehrotra, P., Stam, J., Snesrud, E., Hinkle, M., Lesho, E., McGann, P., McAdam, A. J., Sandora, T. J., Kishony, R., & Priebe, G. P. (2019). Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nature Medicine, 25(11), 1728–1732. https://doi.org/10.1038/s41591-019-0626-9

Reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. renalcarematters.com, reviewed

FDA Philippines registration

1 current food-supplement registration under the brand RENADYL. Registration status changes; confirm a product's current status on the FDA verification portal using its FR number.

Verify on PH FDA portal

3 PROBIOTIC STRAINS (BIFIDOBACTERIUM LONGUM, STREPTOCOCCUS THERMOPHILUS, LACTOBACILLUS ACIDOPHILUS) FOOD SUPPLEMENT CAPSULE

Ingredients
  • Bifidobacterium longum
  • Streptococcus thermophilus
  • Lactobacillus acidophilus
As registered: 3 PROBIOTIC STRAINS (BIFIDOBACTERIUM LONGUM, STREPTOCOCCUS THERMOPHILUS, LACTOBACILLUS ACIDOPHILUS)
FR number
FR-4000008900429 · verify on the FDA portal
Registered as
Food supplement
Form
Capsule
Company
GOODFELLOW PHARMA CORPORATION
Issued
August 13, 2025
Valid until
May 8, 2031
FDA risk class
High Risk
Application
Amendment
For health professionals. Data come from the FDA Philippines food-product registration database and may lag behind the official record. A food-supplement registration means the product may be sold as food; it is not an approval of safety or efficacy for any disease. Not a substitute for clinical judgment.